Introduction
============

Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer related deaths in China [@B1]. Surgical resection is most effective treatment among the numerous therapeutic methods for HCC. However, due to the high rate of recurrence or metastasis (50-70% at 5 year) after surgery [@B2], hinders further improvements in HCC survival [@B3]. The identification of novel effective biomarkers to classify patients with low or high risk at survival and recurrence, would provide a guide to clinicians to select therapeutic strategies for each patients and provide personalized therapy according to the predicted risk of survival or recurrence [@B3]-[@B5].

Niemann-Pick C1-like 1 (NPC1L1) protein plays key rules in intestinal cholesterol absorption [@B6]. NPC1L1 is highly expressed in the human liver and intestine [@B6], [@B7]. In humans, it has been reported that ezetimibe, a cholesterol absorption inhibitor that may reduce plasma cholesterol by inhibiting NPC1L1 function in both intestine and liver, and hepatic NPC1L1 may have evolved to protect the body from excessive biliary loss of cholesterol [@B8]. NPC2 is a small secretory protein (molecular mass is 19-23kDa) which is widely expressed in the various body cells and specifically binds un-esterified sterols, and free cholesterol [@B9], [@B10].

Yamanashi et al. has been reported that, NPC1L1 down-regulates the expression and secretion of NPC2 by inhibiting its maturation and accelerating its degradation. They also proposed that NPC2 functions as a regulator of intracellular cholesterol trafficking and biliary cholesterol secretion. Therefore, in addition to its role in cholesterol re-uptake from the bile by hepatocytes, and hepatic NPC1L1 may control cholesterol homeostasis via the down-regulation of NPC2 [@B11].

However, the expression pattern and prognostic vale role of NPC1L1 and NPC2 in HCC remains unclear. To address this question, we used immunohistochemistry (IHC), Western blot, and Real-time Quantitative PCR to evaluated NPC1L1 and NPC2 expression features in HCC tissue and peritumoral liver tissues. Furethermore, we analyzed the association between NPC1L1 and NPC2 expression levels and clinicopathological factors or the prognosis of patients with HCC.

Materials and methods
=====================

Patients and specimens
----------------------

Three hundred and twenty six HCC formalin-fixed paraffin-embedded (FFPE) specimens were selected randomly and diagnosed at the Eastern Hepatobiliary Surgery Hospital between Jan 2005 and Dec 2011, among which 61 HCC tumor cases with a paired peritumoral tissue was used as expression pattern cohort and 265 HCC tumor cases without a paired peritumoral tissue was used as prognosis cohort. Patients were followed-up until December 2014. For Western blot and Real-time Quantitative PCR analyses 10 paired HCC tissues and peritumoral liver tissues were obtained at same hospital between April 2017 and May 2017 (summarized in supplementary table [S1](#SM0){ref-type="supplementary-material"}).

The enrollment criteria for all patients used in the study were: (1) diagnosis was consistent with histological diagnostic criteria of WHO; (2) pathological diagnosis of hepatocellular lesions; (3) patient had not undergone pre-operative anti-cancer treatment and there was no evidence of extrahepatic metastases; and (4) complete follow-up data was available for prognosis cohort of 265 cases. Institutional review board approval and written informed consent from all patients were obtained. The OS was defined as the interval between surgery and death or the last observation taken. The time-to-recurrence (TTR) was defined as from the date of tumor resection until the detection of tumor recurrence, death or last observation. Patient follow-up was performed every 3 months during the first year after surgery and every 6 months thereafter until December 2014. Follow-up were performed by two physicians unaware of the study. All patients were monitored by abdomen ultrasonography, chest X-ray, and serum alpha fetoprotein (AFP) concentration 1-6 month during the first year after surgery and every 3-6 months thereafter. Computed tomography scanning or magnetic resonance imaging of the abdomen was performed every 6 months or immediately after a recurrence was suspected. The diagnosis criteria for recurrence were equal to that for the preoperative diagnosis. Hematoxylin and eosin (HE) stained slides were made from each FFPE tissue and were reviewed by two experienced hepatopathologists [@B12].

Construction of tissue microarrays and immunohistochemistry (IHC)
-----------------------------------------------------------------

Tissue microarrays construction, IHC and integrated optical density (IOD) measurement performed as the method previously reported [@B12]-[@B14]. All patients of HE-stained slides were reviewed and identified by two experienced pathologists and the representative cores were pre-marked in the paraffin blocks. Tissue cylinders with a diameter of 1.0 mm were punched from the marked areas of each block and incorporated into a recipient paraffin block. Sections of 4 μm-thick were placed on slides coated with 3-aminopropyltriethoxysilane.

Paraffin sections were deparaffinized in xylene and rehydrated through decreasing concentrations of ethanol (100%, 95%, and 85% for 5 min each). Antigens were unmasked by microwave irradiation for 3 min in pH 6.0 citric buffer and cooled at room temperature for 60 min. Endogenous peroxidase activity was blocked by incubation of the slides in 3% H~2~O~2~/phosphate-buffered saline, and non-specific binding sites were blocked with goat serum.

Primary antibody was as follows: Rabbit polyclonal to NPC1L1-HRP (ab201773; Abcam, USA; 1:100 dilution, cytoplasmic or/and membrane staining), Rabbit polyclonal to NPC2 (A5413; Abclonal, USA; 1:2000 dilution, cytoplasmic or/and membrane staining). An EnVision Detection kit (GK500705: Gene Tech, Shanghai, China) was used to visualize NPC2 and NPC1L1 was directly used DAB as the chromogen. Tissue sections were counterstained with hematoxylin for 5 min. Negative control slides omitting primary antibody were created for all assays. For measurement IOD, the image system comprised a Leica CCD camera DFC420 connected to a Leica DM IRE2 microscope (Leica Microsystems Imaging Solutions Ltd, Cambridge, United Kingdom). Photographs of representative fields were captured under high-power magnification (×200) using Leica QWin Plus v3 software. The IODs of in each image were counted and measured using Image-Pro Plus v6.0 software (Media Cybernetics Inc, Bethesda, MD, USA).

Protein extraction and western blotting
---------------------------------------

Western blot was performed according to previous study [@B15]. Briefly, tissue samples were homogenated in a RIPA buffer (Qiagen, China) with a cocktail of proteinase inhibitors (Roche Applied Science, Switzerland) and a cocktail of phosphatase inhibitors (Roche Applied Science). The protein concentrations were determined using the Bicinchoninic Acid (BCA) Kit (Pierce). Proteins were separated by SDS-PAGE and transferred to nitrocellulose membranes (Bio-Rad, Hercules, CA). The membranes were incubated with primary NPC2 antibodies (A5413; Abclonal, USA) at 1:1500, or NPC1L1-HRP (ab201773; Abcam, USA): 1:2000) overnight at 4 °C. After washing the membrane, NPC1L1 was visualised using ECL development solution. For detection of NPC2, secondary antibodies incubated at room temperature for 1\~2 h and NPC2 was visualised using ECL development solution.

RNA isolation and real-time RT-PCR
----------------------------------

Real-time PCR was performed according to previous study [@B15]. Briefly, total RNA was extracted from tissues using TRIzol reagent (Invitrogen, Carlsbad, CA), and reverse transcription was performed using PrimeScript™ RT Reagent Kit (Takara, Dalian, China) according to the manufacturer\'s instructions. The real-time polymerase chain reaction (PCR) was subsequently performed with SYBR Premix Ex Tag (Takara, Dalian, China). The PCR reaction conditions were as follows: 95°C for 15s followed by 40 cycles of 95°C for 5s and 60°C for 30s. The expression levels were normalized against those of the internal reference gene β-actin, the relative expression levels were determined by the following equation: 2-ΔCt (ΔCt=Ct target - Ct β-actin). The related primers were listed as following:

NPC1L1: Forward 5\'-CCAAGTCGACTGGAAGGACC-3\'; Reverse 5\'-AGGGCCTCTGCCTCAGAATA-3\';

NPC2: Forward 5\'-CCAGTACAGATCGTTTCTCATCTCT-3\'; Reverse 5\'-CCGGAGCTCAGTTTCTGCTA-3\';

beta-actin: Forward 5\'-TTGTTACAGGAAGTCCCTTGCC3\'; Reverse 5\'-ATGCTATCACCTCCCCTGTGTG-3\'.

X-tile analysis
---------------

X-tile plots were used for assessment of NPC1L1 and NPC2 expression which was represented as IOD and optimization of cut-points based on outcome [@B16]. Statistical significance was assessed using the cut-off score derived from 265 cases by a standard log-rank method, with P values obtained from a lookup table.

Statistical analysis
--------------------

Statistical analyses were carried out with SPSS statistical software package (SPSS Standard version 13.0; SPSS, Chicago, IL, USA) and GraphPad Prism 5.01. Optimal cut-point which used for survival analyses for NPC1L1 and NPC2 expression was obtained using X-tile software version 3.6.1 (Yale University School of Medicine, New Haven, CT, USA) [@B16]. Statistical significance of the correlation between NPC1L1 and NPC2 expression and patient survival was estimated by the Mantel Cox log-rank test. Correlations between variables, univariate survival analysis and multiple Cox proportional hazards regression were performed using the SPSS statistical software package (SPSS Standard version 13.0; SPSS, Chicago, IL, USA). A significant difference was considered if the P value from a two-tailed test was less than 0.05.

Results
=======

Features of NPC1L1 and NPC2 expressions in HCC tissues and Peritumoral tissues
------------------------------------------------------------------------------

Staining feature of NPC1L1 and NPC2 in HCC showed cytoplasmic or/and membrane immunoreactivity for both HCC tissues and peritumoral tissues, respectively (Figure [1](#F1){ref-type="fig"} A-F). To compare the expression levels of NPC1L1 and NPC2 in HCC tumor tissues and peritumoral tissue in expression pattern cohort (61 cases), IOD which represent the expression level from 61 HCC tumors and paired peritumoral tissue were submitted to GraphPad Prism software. As shown in Figure [1](#F1){ref-type="fig"} G, expression of NPC1L1 and NPC2 were frequently lower in HCC tumor tissues than that in peritumoral tissue (p\<0.0001 for NPC1L1; p=0.0001 for NPC2).

In addition, expression level of NPC1L1 and NPC2 were analyzed in 10 paired HCC and peritumoral tissue using Western blot and Real-time Quantitative PCR for further confirmation. As shown in Figure [2](#F2){ref-type="fig"}A and Figure [2](#F2){ref-type="fig"}B, NPC1L1 and NPC2 expressions were significantly reduced in HCC tissue (p=0.0002 for NPC1L1, p=0.0489 for NPC2). In parallel, the mRNA expression of NPC1L1 and NPC2 expression levels also reduced in HCC tissue compared to peritumoral tissue.

Cut-off point based on outcome and Kaplan-Meier analysis
--------------------------------------------------------

To obtain the best cut-off point of NPC1L1 and NPC2 expression level for survival analysis in 265 HCC cases of prognosis cohort, the X-tile program was used. Using a standard log-rank method, best cut-off points were obtained with minimum p values from a lookup tables for OS and TTR.

As results, 222 cases were divided into low NPC1L1 expression group and 43 cases were divided into high NPC1L1 expression cases. For, NPC2, 184 cases were divided into low NPC2 expression group and 81 cases were divided into high NPC2 expression cases. After then, the OS and TTR curves were depicted by Kaplan-Meier analysis using SPSS 13 software. Results showed that mean OS time for HCC patients expressing low levels of NPC1L1 was 53.5 months, compared with 59.1 months for those expressing high levels of NPC1L1 (P=0.027, log-rank test; Figure [3](#F3){ref-type="fig"} A). The mean TTR for HCC patients expressing low levels of NPC1L1 was 35.9 months, compared with those expressing high levels of NPC1L1 was 50.6 months (P=0.017, log-rank test; Figure [3](#F3){ref-type="fig"} B). For NPC2, the mean OS time for HCC patients expressing low levels of NPC2 was 45.7 months, compared with 65.4 months for those expressing high levels of NPC2 (P=0.01, log-rank test; Figure [3](#F3){ref-type="fig"} C). The mean TTR for HCC patients expressing low levels of NPC2 was 34.8 months, compared with those expressing high levels of NPC2 was 46.4 months (P=0.012, log-rank test; Figure [3](#F3){ref-type="fig"} D).

Association NPC1L1 and NPC2 combination with HCC patient\'s OS and TTR
----------------------------------------------------------------------

Based on the NPC1L1 and NPC2 expression levels, we classified the 265 HCC patients (prognosis cohort) into 3 groups: group 1 defined as patients with low NPC1L1 expression and low NPC2 expression; group 2 defined as patients with low NPC1L1 expression and high NPC2 expression, or high NPC1L1 and low NPC2 expression; group 3 defined as patients with high expressions for both NPC1L1 and NPC2.

Using the Kaplan-Meier method, patients with the low NPC1L1/low NPC2 expression (group 1) had the shortest OS (mean 45.0 months) and TTR (mean 34.2 months), whereas patients with the high NPC1L1/high NPC2 expression (group 3) had the longest OS (mean 61.1 months) and TTR (mean 54.4 months). While, patients in group 2 (NPC1L1 and High NPC2 expression, high NPC1L1 and low NPC2 expression) had moderate OS (mean 61.7 months) and TTR (mean 41.6 months) (Figure [4](#F4){ref-type="fig"}).

Association of NPC1L1 and NPC2 expression with clinicopathological features of HCC patients
-------------------------------------------------------------------------------------------

Next we investigated the association between NPC1L1 and NPC2 expression which according to the cut-off point determined by outcome based classification, and clinicopathological factors in 265 HCC patients. Result revealed that NPC1L1 expression was associated with serum AFP (p=0.007), TNM (p=0.015), tumor differentiation (p=0.003), vascular invasion (p=0.004) and did not associated with other clinicopathological factors (Table [1](#T1){ref-type="table"}). In addition, NPC2 expression were associated with serum AFP (p=0.0001), tumor differentiation (p=0.012), vascular invasion (p=0.042), and did not associated with other clinicopathological factors (Table [1](#T1){ref-type="table"}).

Univariate and multivariate survival analyses
---------------------------------------------

Univariate analysis showed that serum AFP, liver cirrhosis, TNM stage, tumor size, tumor number, tumor differentiation, vascular invasion, NPC1L1, NPC2, and NPC1L1/NPC2 combination was associated significantly with OS and TTR, respectively (p value for OS were \<0.0001, 0.036, \<0.0001, \<0.0001, \<0.0001, 0.014, 0.010, 0.030, 0.011, and 0.004; p value for TTR were 0.001, 0.004, \<0.0001, \<0.0001, \<0.0001, 0.009, 0.023, 0.020, 0.014, and 0.004) (Table [2](#T2){ref-type="table"}).

Multivariate analysis was performed using the Cox multivariate proportional hazard regression model in a stepwise manner (forward, conditional likelihood ratio). Factors that indicated significance in the univariate analysis were entered into a Cox multivariate proportional hazard regression analysis. Results showed that serum AFP, liver cirrhosis, tumor size, tumor number, and NPC1L1/NPC2 combination were the independent prognostic factors for OS and liver cirrhosis, tumor size, tumor number, and NPC1L1/NPC2 combination were the independent prognostic factors for TTR (Table [2](#T2){ref-type="table"}).

Discussion
==========

A multinational, long-term HCC survival analysis indicates the significant improvement in outcomes over the past three decades observed in both the East and the West for HCC patients after surgical resection [@B17]. In detail, postoperative mortality and overall survival rates after major hepatectomy were improved over time with 5-year survival rates of 30 %, 40 %, and 51 % for the years 1981-1989, 1990-1999, and the most recent era of 2000-2008, respectively [@B17]. However, from the above dada, we learn that almost half of the HCC patients still with unsatisfactory prognosis.

The prognosis of HCC patients is often poor because of the high risk of recurrence and metastasis after curative resection especially in HBV-related HCC [@B18]. Therefore, the identification of prognostic markers to identify the risk of prognosis of HCC patients after surgery is still critical.

Recently, it was reported that NPC2 may regulates liver cancer progression via modulating ERK1/2 pathway and low NPC2 protein expression levels may predict poor OS of postoperative HCC patients in small size of patients number (n=50) [@B19]. In addition, NPC1L1 inhibition has been shown to prevent metabolic disorders such as fatty liver disease, obesity, diabetes, and atherosclerosis [@B20]. However, there was no report concerning about that NPC1L1 in HCC. In 2006, Jiang et al., summarized that decreased serum levels of cholesterol and apoAI may indicate a poor prognosis [@B21]. Recently, a Taiwanese based cohort study reported that, serum cholesterol level is a potential risk factor for BMI associated surgical outcome after hepatectomy [@B22]. Taken together, our results may be a new Insight into serum cholesterol level and NPC1L1 in HCC.

In conclusion, our study is first to demonstrate the expression pattern of NPC1L1 in HCC tumor tissue and peritumoral tissues, and was the first to demonstrate the prognostic value of NPC1L1, and NPC1L1/NPC2 combination is an independent prognostic factor for OS and TTR in postoperative HCC patients. Thus, undertaking the expression level of NPC1L1 and NPC2 in HCC patient tissues may provide a clinicians risk information about OS and TTR of postoperative HCC patient and maybe helpful to study mechanism for relationship between cholesterol and HCC.

In this present study, we found that NPC1L1 was decreased in HCC compared with paired peritumoral liver tissues, and low NPC1L1 protein expression may predict poor OS and TTR of postoperative HCC patients. We further validated that low NPC2 protein expression levels may predict poor OS of postoperative HCC patients (n=265), and found that low NPC2 protein expression levels may predict poor TTR of postoperative HCC patients. Interestingly, we further found that, NPC1L1/NPC2 combination is an independent prognostic factor for OS and TTR in postoperative HCC patients.
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======================
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![**NPC1L1 and NPC2 expression in peritumoral tissue and paired HCC tissues by immunohistochemistry.** Expression features of NPC1L1 in (A) paired peritumoral tissue and (B) HCC tissue (×200). Expression of NPC2 in (C) paired peritumoral tissue and (D) HCC tissue (×200). Picture contains both HCC and peritumoral tissue for (E) NPC1L1 and (F) NPC2 (×100). (G) Scatter plot showing the mean staining intensity of paired peritumoral tissue (P) and HCC tumor tissue (T) (p\<0.0001 for NPC1L1, p=0.0001 for NPC2).](jcav09p0556g001){#F1}

![**NPC1L1 and NPC2 expression in peritumoral tissue and paired HCC tissues by Wetern-blot and Real-time Quantitative PCR.** (A) NPC1L1 and NPC2 expression was detected by Western blot analyses in 10 paired HCC tissue (T) and peritumoral tissue (P). (B) Quantitation of proteins from Western blot analyses shows that both NPC1L1 and NPC2 expressions significantly reduced in HCC tissue (T) (p=0.0002 for NPC1L1, p=0.0489 for NPC2). The mRNA expression of NPC1L1 and NPC2 was detected by Real-time Quantitative PCR. Results clearly shows that mRNA expression levels also reduced in HCC tissue (T) compared to peritumoral tissue (P) for both NPC1L1 (C) and NPC2 (D).](jcav09p0556g002){#F2}

![**Kaplan-Meier survival analyses of NPC1L1 and NPC2 in HCC patients.** (A) Probability of survival of postoperative HCC patients: low expression of NPC1L1 (n=222, mean=53.5 months), high expression of NPC1L1 (n=43, mean=59.1 months). (B) Probability of recurrence of postoperative HCC patients: low expression of NPC1L1 (n=222, mean=35.9 months), high expression of NPC1L1 (n=43, mean=50.6 months). (C) Probability of survival of postoperative HCC patients: low expression of NPC2 (n=184, mean=45.7 months), high expression of NPC1L1 (n=81, mean=65.4 months). (D) Probability of recurrence of postoperative HCC patients: low expression of NPC2 (n=184, mean=34.8 months), high expression of NPC1L1 (n=81, mean=46.4 months).](jcav09p0556g003){#F3}

![**Kaplan-Meier survival analyses of NPC1L1/ NPC2 combination in HCC patients.** (A) Probability of survival of postoperative HCC patients: all low expression (n=169, mean=45.0 months), NPC1L1 low/NPC2 high or NPC1L1 high/NPC2 low expression (n=68, mean=61.7 months), all high expression (n=28, mean=61.1 months) (B) Probability of recurrence of postoperative HCC patients: all low expression (n=169, mean=34.2 months), NPC1L1 low/NPC2 high or NPC1L1 high/NPC2 low expression (n=68, mean=41.6 months), all high expression (n=28, mean=54.4 months)](jcav09p0556g004){#F4}

###### 

Association of NPC1L1 and NPC2 expression with clinicopathological features in 265 cases of HCC patient.

  Variable                NPC1L1                         NPC2                                
  ----------------------- ------------ ----- ----------- ----------- -- ----- -------------- -------
  sex                                                    0.738                               0.783
                          Male         192   38                         159   71             
                          Female       30    5                          25    10             
  age                                                    0.975                               0.072
                          ≤ 50         109   21                         97    33             
                          \>50         113   22                         87    48             
  HBsAg                                                  0.123                               0.083
                          negative     31    10                         21    16             
                          positive     191   33                         159   65             
  serum AFP                                  **0.007**                        **\<0.0001**   
                          ≤ 20 ng/ml   71    23                         50    41             
                          \>20ng/ml    151   20                         131   40             
  liver cirrhosis                            0.666                            0.779          
                          no           70    15                         60    25             
                          yes          152   28                         124   56             
  TNM                                                    **0.015**                           0.121
                          I            61    21                         51    31             
                          II           124   19                         101   42             
                          III-IV       37    3                          32    8              
  Child-pugh class                           0.305                            0.351          
                          A            201   41                         170   72             
                          B            21    2                          14    9              
  tumor size                                 0.682                            0.617          
                          ≤5 cm        106   22                         87    41             
                          \>5 cm       116   21                         97    40             
  tumor number                               0.417                            0.988          
                          single       168   35                         141   62             
                          multiple     54    8                          43    19             
  tumor differentiation                      0.003                            **0.012**      
                          well         15    10          .              11    14             
                          moderate     205   33                         172   66             
                          Poor         2     0                          1     1              
  vascular invasion                          0.004                            **0.042**      
                          no           73    24                         60    37             
                          yes          149   19                         124   44             

###### 

Univariate and multivariate analyses of factors associated with OS and TTR in 265 cases of HCC patient.

  --------------------------------------------------------------------------------------------------------------------------------------------
  Factors                              OS             TTR                                                                       
  ------------------------------------ -------------- ------- ------------- -------------- -------------- ------- ------------- --------------
  sex: Male *vs* Female                0.493                                               0.985                                

  age: ≤50 *vs* \>50                   0.716                                               0.787                                

  HBsAg: positive *vs* negative        0.091                                               0.069                                

  serum AFP (ng/ml): ≤20 *vs* \>20     **\<0.0001**   1.527   1.008-2.315   **0.046**      **0.001**                            

  liver cirrhosis: yes *vs* no         **0.036**      1.747   1.165-2.620   **0.007**      **0.004**      1.832   1.282-2.620   **0.001**

  TNM: I *vs* II *vs* III-IV           **\<0.0001**                                        **\<0.0001**                         

  Child-pugh: A *vs* B                 0.135                                               0.174                                

  tumor size: ≤5 *vs* \>5              **\<0.0001**   2.897   1.956-4.292   **\<0.0001**   **\<0.0001**   2.214   1.603-3.057   **\<0.0001**

  tumor number: single *vs* multiple   **\<0.0001**   1.735   1.192-2.527   **0.004**      **\<0.0001**   2.077   1.483-2.910   **\<0.0001**

  tumor differentiation: well *vs*\    **0.014**                                           **0.009**                            
  moderate *vs* poor                                                                                                            

  vascular invasion: no *vs* yes       **0.010**                                           **0.023**                            

  NPC1L1 expression                    **0.030**                                           **0.020**                            

  NPC2 expression                      **0.011**                                           **0.014**                            

  NPC1L1/NPC2 combination: low\        **0.004**      0.705   0.507-0.957   **0.024**      **0.004**      0.701   0.547-0.898   **0.005**
  vs High                                                                                                                       
  --------------------------------------------------------------------------------------------------------------------------------------------
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